Table of Content . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________ Form 10-K ____________________________________________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition pe ...

Companies displaying incessant earnings growth will continue to captivate almost everyone in the investment world, from top brass to research analysts. This is because earnings are a measure of the money a company is making. Still, earnings acceleration works better when lifting the stock price.Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in the stock price. Some of the notable companies to have witnessed solid earnings acceleration as of now are Prot ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate rev ...

Company Performance - AxoGen (AXGN) shares have increased by 8.8% over the past month and reached a new 52-week high of $10.65, with a year-to-date gain of 51.8% compared to 7.9% for the Zacks Medical sector and 6.3% for the Zacks Medical - Instruments industry [1] - The company has consistently exceeded earnings expectations, reporting EPS of $0.01 against a consensus estimate of $-0.08 in its last earnings report on November 7, 2023 [2] Financial Projections - For the current fiscal year, AxoGen is projected to earn $0.03 per share on revenues of $158.8 million, with a year-over-year earnings growth of 118.75% [2] - For the next fiscal year, earnings are expected to rise to $0.17 per share on revenues of $178.5 million, representing a year-over-year change of 12.41% [2] Valuation Metrics - AxoGen's current trading valuation is at 345.7X current fiscal year EPS estimates, significantly higher than the peer industry average of 27.9X [4] - On a trailing cash flow basis, the stock trades at 5X compared to the peer group's average of 13.1X, indicating a less favorable value perspective [4] Zacks Rank and Style Scores - AxoGen holds a Zacks Rank of 2 (Buy) due to favorable earnings estimate revisions from analysts, suggesting potential for future growth [5] - The company has a Value Score of C, a Growth Score of B, and a Momentum Score of C, resulting in a combined VGM Score of B [3] Industry Comparison - Artivion, Inc. (AORT), a peer in the industry, has a Zacks Rank of 1 (Strong Buy) and has shown strong earnings performance, beating consensus estimates by 184.62% [6] - The Medical - Instruments industry is positioned in the top 38% of all industries, indicating favorable conditions for both AxoGen and Artivion [6]

Earnings growth captivates almost everyone, from the top brass to research analysts. After all, earnings are a measure of the money a company is making.Still, earnings acceleration works even better when lifting the stock price. Studies have shown that most successful stocks have seen an acceleration in earnings before an uptick in their price.Earnings acceleration is the incremental growth in a company’s earnings per share (EPS). In other words, if the rate of a company’s quarter-over-quarter earnings grow ...

Company Overview - Axogen, Inc. (NASDAQ:AXGN) is a leader in developing and marketing surgical solutions for peripheral nerve injuries [3] - The company focuses on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair [3] - Axogen aims to restore peripheral nerve function and improve the quality of life for patients with nerve damage through innovative and clinically proven solutions [3] Product Portfolio - Axogen's product offerings include Avance® nerve graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, and Axoguard Nerve Cap® [5] - The products are designed for two main application categories: scheduled non-trauma procedures and emergent trauma procedures [4] - The portfolio is available in multiple countries, including the United States, Canada, Germany, the United Kingdom, Spain, and South Korea [5] Upcoming Financial Results - Axogen will report its 2023 fourth quarter and full-year financial results on March 5, 2024, before the market opens [1] - Following the release, management will host a conference call and webcast at 8 a.m. ET [1] - Investors can participate in the conference call via phone or listen live on the company's website [1][2]

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it.The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the stock alive.Our " ...

ALACHUA, Fla. and TAMPA, Fla., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced making Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) in connection with the employment and appointment of John Manning to the position of Area Vice President of Sales. Mr. Manning will report to Doris Quackenbush, Vice President of Sales. In connection with the commencement of his employm ...

Core Insights - Axogen, Inc. announced positive topline results from its REPOSE clinical study, demonstrating that Axoguard Nerve Cap is statistically superior to standard-of-care neurectomy in reducing total pain for symptomatic neuroma patients over a 12-month follow-up period [1][2] - The study met its primary endpoint for non-inferiority in pain reduction as measured by the visual analog scale, with a p-value of less than 0.05 [1][3] Company Overview - Axogen is a leader in developing and marketing surgical solutions for peripheral nerve injuries, focusing on technologies that enhance nerve regeneration and repair [5] - The company offers a comprehensive portfolio of products for both scheduled and emergent trauma procedures, addressing various conditions caused by nerve defects or injuries [6][7][8] Product Details - Axoguard Nerve Cap is a proprietary surgical implant made from porcine submucosal extracellular matrix, designed to protect peripheral nerve ends and reduce the development of symptomatic neuromas [4][8] - The product is part of a broader range of offerings that includes Avance® nerve graft and Axoguard Nerve Connector®, aimed at improving outcomes for patients with peripheral nerve damage [8]

AxoGen, Inc. (NASDAQ:AXGN) Q3 2023 Earnings Conference Call November 7, 2023 8:00 AM ET Company Participants Adanna Alexander - IR Consultant Karen Zaderej - Chairman, CEO and President Pete Mariani - EVP and CFO Conference Call Participants Michael Sarcone - Jefferies Caitlin Cronin - Canaccord Genuity Dave Turkaly - JMP Securities Operator Greetings. Welcome to the AxoGen Reports Third Quarter 2023 Financial Results. At this time, all participants are in a listen-only mode. A question-and-answer session w ...